Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Pappadopulos

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Pediatrics|May 30, 2012
Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing managementNancy Scotto Rosato, Christoph U Correll, Elizabeth Pappadopulos, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2017
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysisRaymond W Lam, Dalia B Wajsbrot, Ellen Meier, et al.
The International Journal of Neuropsychopharmacology|December 21, 2012
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia TrialW Wolfgang Fleischhacker, Cynthia O Siu, Robert Bodén, et al.
Psychiatric Services (Washington, D.C.)|February 28, 2007
Applying theory-driven approaches to understanding and modifying clinicians' behavior: what do we know?Matthew B Perkins, Peter S Jensen, James Jaccard, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 13, 2018
Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysisSripal Bangalore, Ruchitbhai Shah, Elizabeth Pappadopulos, et al.
Journal of Child and Adolescent Psychopharmacology|December 27, 2011
Experts' recommendations for treating maladaptive aggression in youthElizabeth Pappadopulos, Nancy Scotto Rosato, Christoph U Correll, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Menopause (New York, N.Y.)|June 20, 2023
Efficacy and safety of lemborexant in midlife women with insomnia disorderMasakazu Terauchi, Jocelyn Y Cheng, Jane Yardley, et al.
Journal of Medical Economics|May 30, 2020
Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United StatesEric Armbrecht, Anuj Shah, Patricia Schepman, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Psychiatric Research|September 11, 2020
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysisMasaki Kato, Yuko Asami, Dalia B Wajsbrot, et al.
Pediatrics|May 30, 2012
Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing managementNancy Scotto Rosato, Christoph U Correll, Elizabeth Pappadopulos, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2017
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysisRaymond W Lam, Dalia B Wajsbrot, Ellen Meier, et al.
The International Journal of Neuropsychopharmacology|December 21, 2012
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia TrialW Wolfgang Fleischhacker, Cynthia O Siu, Robert Bodén, et al.
Psychiatric Services (Washington, D.C.)|February 28, 2007
Applying theory-driven approaches to understanding and modifying clinicians' behavior: what do we know?Matthew B Perkins, Peter S Jensen, James Jaccard, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 13, 2018
Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysisSripal Bangalore, Ruchitbhai Shah, Elizabeth Pappadopulos, et al.
Journal of Child and Adolescent Psychopharmacology|December 27, 2011
Experts' recommendations for treating maladaptive aggression in youthElizabeth Pappadopulos, Nancy Scotto Rosato, Christoph U Correll, et al.
International Clinical Psychopharmacology|June 10, 2017
Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT studyKoichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, et al.
Menopause (New York, N.Y.)|June 20, 2023
Efficacy and safety of lemborexant in midlife women with insomnia disorderMasakazu Terauchi, Jocelyn Y Cheng, Jane Yardley, et al.
Journal of Medical Economics|May 30, 2020
Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United StatesEric Armbrecht, Anuj Shah, Patricia Schepman, et al.
Pageof 4